suggested that inhibition of CXCR4 regulated tumoral, stem cell, and immune mechanisms via adjunctive CXCR4 antagonists, which might help to overcome antiangiogenic therapy resistance, benefiting patients with GBM (41). Here, CXCR4 is linked to glioblastoma.